Then I started to hear about friends of friends, and then now I have personal friends that are taking it as well as family members
Preserving Lean Body Mass in Patients Taking GLP1 for Weight Loss. Endocrinology Advances in Motion, 6 June 2025.
The lawsuit was filed on August 2, 2023 in the U.S
1 In adults with obesity, along with diet and exercise, A well-studied safety profile for adults with obesity: Pooled safety data from 2 weight-management clinical trials evaluating Wegovy HD 7.2 mg 1 Wegovy HD (semaglutide) injection 7.2 mg had a safety profile consistent with Wegovy 2.4 mg 1,3 5% of patients with Wegovy HD 7.2 mg pen, 5% of patients with Wegovy 2.4 mg pen, and 2% of patients with placebo permanently discontinued as a result of adverse reactions 1 The most common adverse reactions leading to discontinuation were gastrointestinal disorders: 3% of patients with Wegovy HD 7.2 mg pen, 3% of patients with Wegovy 2.4 mg pen, and 0.3% of patients with placebo 1 Includes allodynia, burning sensation, dysesthesia, hyperesthesia, hyperpathia, pain of skin, paresthesia, sensitive skin, skin burning sensation, skin discomfort, and skin sensitization

Compounding is legally permitted primarily when FDA-approved drugs are in shortage, or when a patients unique medical need cannot be met by commercial products
This is an opt-in program